Background: The aim of this study was to quantify the intracellular pathway proteins ERK, AKT, 26 cyclin d and p70s6k in localized colon cancer tissue to investigate the possible prognostic values 27 and the ability to be used as screening markers for upstream mutations. Methods: Colon cancer 28 tissue and autologous reference tissue were collected from 176 patients who underwent surgery for 29 colon cancer. Assays for quantifying ERK, AKT, cyclin d and p70s6k proteins were developed 30 using single molecule array (Simoa). KRAS/BRAF/PIK3CA mutation status was determined using 31 droplet digital PCR. Results: Patients with BRAF mutations had decreased concentrations of ERK 32 (p=0.0002), AKT (p=0.00004) and cyclin d (p=0.001) while no significant differences were found 33 between patients with KRAS mutations and Wild type (Wt) patients. None of the investigated 34 protein concentrations were associated with disease free survival or overall survival, if including all 35 patients. However, when stratifying according to mutation status, significant correlations to overall 36 survival were seen for patients with BRAF mutations and AKT (p=0.003) or ERK (p=0.046) and 37 for patients with KRAS mutations and p70s6k (p=0.04). Furthermore, the combination of genetic 38 mutations, stage 2 disease, and all of the investigated pathway proteins showed significant 39 correlations to overall survival. Conclusions: There is a strong correlation between pathway protein 40 concentrations and mutational BRAF status. Overall survival in colon cancer patients depend both 41 on gene mutation status and pathway protein concentrations. As significant correlations were found 42 between BRAF mutations and ERK, AKT and cyclin d, concentration measurements of these 43 pathway proteins might be useful as screening for upstream mutations.
galactopyranoside; AEB, average number of enzyme per bead.
Introduction 54
The intracellular signaling network of the epidermal growth factor receptor (EGFr) consists of two 55 key signal pathways. The mitogen-activated protein kinase (MAPK) also termed 56 RAS/RAF/MEK/ERK and the phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT) 57 pathways. They interact in a complex coordinated manner to regulate all stimulated cellular 58 processes and have been described in detail [1;2] . Both ERK and AKT activate more than 100 70 Activation and dysregulation of intracellular signaling pathways plays a critical role in cancer. A 71 frequent alteration in signaling in colorectal cancer is in the RAS and RAF proteins which result in 72 the proteins being constitutively active and stimulating the ERK signaling pathway even though no 73 signal is present. The occurrence of KRAS and BRAF mutations in colorectal cancers has been 74 found to be approximately 40% and 10-25%, respectively [7-9]. Also dysregulation in the 75 PI3K/AKT pathway due to activating mutations in PI3K (PIK3CA) has been identified in colorectal 5 76 cancer [10-12] and PIK3CA mutations have been found to commonly coexist with KRAS or BRAF 77 mutations [11] .
78
The use of inhibitors against growth factor receptors and tyrosine kinase activators has become 79 standard anti-cancer therapy during the last 10 to 15 years. Some of these monoclonal antibodies 80 used in the treatment are Cetuximab as a blocker to EGFr in colorectal cancer and the Trastuzumab 81 HER2 receptor blocker in breast cancer. Mutations in the receptor proteins or in the pathway 82 proteins result in resistance to treatment using these monoclonal antibodies. It is therefore important 83 to detect such mutations at an early phase before treating the patients as it can be predicted whether 84 the treatment will be without effect and thus the patients will only experience side effects of the 85 treatment.
86
Usually known mutations are diagnosed using PCR or sequencing which are laborious, time 87 consuming, expensive and causes a delay of several days for reporting. In the future, the number of 88 mutations in the pathway proteins will increase and hence will the expense for sequencing or 89 detecting mutations by PCR. Alternative methodology to detect activation of the intracellular 90 pathway proteins could gain importance especially if such methods would be both faster and 91 considerable cheaper. 92 We therefore aimed to see whether quantification of pathway proteins in colon cancer tissue might 93 reflect upstream mutations and to detect whether changes in concentrations might be correlated to 94 effect of treatment or clinical outcome. We developed quantitative protein assays for measuring The development of quantitative methods and the measurement of the pathway proteins was 123 performed on the automated Simoa HD-1 Analyzer platform (Quanterix©, Lexington, MA, USA).
124
This instrument uses the same reagents as conventional ELISA but uses femtoliter-sized reaction 125 chambers approximately 2 billion times smaller than conventional ELISA. This will result in a rapid 126 buildup of fluorescence if a labeled protein is present which make it possible to detect single 127 molecules. The instrument has previously been described in detail [13] . were analyzed in replicates of at least 6 in one assay and the total CV% was calculated from runs 213 from different days ( Table 1) . Autologous reference tissue and cancer tissue. 219 tERK, pERK, tAKT, pAKT, cyclin d and pp70s6k were measured in both autologous reference 220 tissue and colon cancer tissue (Fig 3 and Table 2 ). Both pERK and tERK were found to be down-221 regulated in cancer tissue (p= 0.001) while pAKT, tAKT, cyclin d and pp70s6k showed no 222 differences between the tissues. Testing for variance differences between the tissue groups using 223 Modified-Levene Equal Variance Test showed significant differences (p< 0.0001) for tAKT, 224 pAKT, tERK and cyclin d. The median and range are shown for each pathway protein. Correlations between the pathway proteins. 233 Associations between the pathway proteins in autologous reference tissue or cancer tissue were 234 investigated. The Spearman's rank correlation coefficients are shown in Table 3 . In the autologous 235 reference tissue the correlation between tAKT and pp70s6k was statistically significant (p= 0.0003).
236
All other cases also showed statistically significant correlations (p<0.000001). Furthermore 237 significant correlations were found between cancer tissue and autologous reference tissue regarding 238 tAKT (p=0.003) and cyclin d (p=0.03). In this study quantitative methods were developed using Simoa technology for measuring AKT, 283 ERK, cyclin d and pp70s6k in localized colon cancer tissue to investigate their correlation to 284 prognosis and their relation to upstream mutations in the pathways.
285
The colon tissues were stored in RNAlater which might be a limitation of the study since the 286 RNAlater solution contains a high level of ammonium sulfates which denature proteins. We 287 therefore ensured that the developed assays were compatible with denatured proteins. tumors and differences in prognostic value in the two groups may be possible. Also method 308 differences, mutation data, sample sizes are some of the factors that might explain the divergent 309 results.
310
Cancer tissues with genetic mutations result in a constitutive activation of the intracellular 311 pathways. It is therefore plausible, that an increased activation and turn-over may lead to an over-312 production or consumption of native proteins as seen in the complement and coagulation pathway 313 cascades. In this study there was an overall statistically significant correlation between pathway 314 protein concentrations and mutational status. However, the change in pathway protein 315 concentrations is too small to be used as screening indicators for mutations in practical medical use 316 and our hypothesis could therefore not be confirmed. As in the complement and coagulation 317 pathways the correct way to detect an increase in activity is to quantify not the native proteins but 318 degradation or split products from the single intracellular pathway proteins. Therefore, we now aim 319 to develop specific antibodies and methods to measure these degradation products, as previously 320 done for complement C3d [28;29]. We believe this approach will increase both the prediction of 321 mutations and survival. 
